I
ntroducing STAT’s Biotech Q4 Scorecard: Ten companies with important clinical trial and FDA milestones scheduled to read out over the next three months. We’ll use emojis to track the winners and losers as the outcomes are announced. Scroll down for a short explanation of each company and its pivotal readout.
This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.
Hello Adam,
Are you considering the KITE/GILEAD axi-cel approval on/about November 29 FDA PDUFA date a forgone conclusion? It won’t exactly “break” Gilead with a CRL (Complete Response Letter) but if that happens, don’t you think it would result in a huge drop in the stock price?